Under the chairmanship of the President of the Republic of Uzbekistan, Shavkat Mirziyoyev, a video conference was held dedicated to increasing production capacities in the pharmaceutical industry and accelerating the transfer of modern technologies.
During the meeting, the head of Nova Pharm, Satvinder Singh, expressed his views on the prospects for the development of the pharmaceutical industry and the company’s ongoing projects.
According to him, the state is currently paying significant attention to the development of the pharmaceutical industry, creating favorable conditions for domestic producers.
“During today’s dialogue, we raised real issues we face in our operations, and we are confident that prompt solutions will be found. This will be an important factor in obtaining international GMP standards, which will open broad opportunities for reducing imports and developing export potential,” noted Satvinder Singh
He emphasized that for local entrepreneurs, reducing import supplies opens new opportunities for the development of domestic production.
Satvinder Singh also reported that Nova Pharm has already signed contracts for a new investment project worth 25 million dollars. In addition, a project worth 30 million dollars is being implemented in Uzbekistan, which will allow exporting pharmaceutical products to neighboring Afghanistan.
The company’s enterprise is located in Surkhandarya region, which creates additional opportunities for developing export supplies thanks to the existing trade route. According to Satvinder Singh, creating similar trade corridors for other Central Asian regions could significantly expand opportunities for entrepreneurs.
In conclusion, Satvinder Singh expressed gratitude to the President of the Republic of Uzbekistan for his attention and support for the development of the pharmaceutical industry.
Additionally, the Hokim of Surkhandarya region, Ulugbek Kosimov, in his interview, emphasized the significance of Nova Pharm for the region and reported that “this year the company’s production is expanding: the share of pharmaceutical products is increasing from 60% to 80%.” This opens new opportunities for increasing export volumes and strengthening the company’s position in both domestic and foreign markets.